Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 18/20 | 0.42 |
| ▸ | PPARG | P37231 | 17/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | PTGIR | P43119 | 1/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5410800 | 0.89 | PPARA (0.45) | PPARAPPARGPPARDPTGIRPTGDR | |
| SCHEMBL5416569 | 0.88 | PPARA (0.44) | PPARAPPARGPPARD | |
| SCHEMBL5110418 | 0.86 | PPARG (0.54) | PPARAPPARGPPARDPTGIRPTGDR | |
| SCHEMBL5125185 | 0.85 | PPARG (0.54) | PPARAPPARGPPARDPTGIRPTGDR | |
| SCHEMBL5414108 | 0.85 | PPARA (0.46) | PPARAPPARGPPARDPTGIRPTGDR | |
| SCHEMBL5110525 | 0.85 | PPARG (0.54) | PPARAPPARGPPARDPTGIRPTGDR | |
| SCHEMBL5125204 | 0.85 | PPARG (0.54) | PPARAPPARGPPARDPTGIRPTGDR | |
| Potassium SCHEMBL5110530 | 0.85 | PPARG (0.54) | PPARAPPARGPPARDPTGIRPTGDR | |
| SCHEMBL5413598 | 0.85 | PPARG (0.51) | PPARAPPARGPPARD | |
| SCHEMBL5417547 | 0.85 | PPARA (0.47) | PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220864-B2 | Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-7220864-B2 | Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-7220864-B2 | Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-20060287304-A1 | Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2006-12-21 | — | — | US | disclosed |
| EP-1726586-A1 | Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
| US-20040138213-A1 | Dihydronaphthalene derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1354879-A1 | DIHYDRONAPHTHALENE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287304-A1 | Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient | SREBF1, NR1H2, NR1H3 | PPARA 6/4885PPARG 15/4885PPARD 13/4885 |
| US-20040138213-A1 | Dihydronaphthalene derivative compounds and drugs containing these compounds as the active ingredient | SREBF1, NR1H2, NR1H3 | PPARA 14/4885PPARG 26/4885PPARD 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.